Aevi (GNMX) PT Lowered to $0.20 at Jefferies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aevi (GNMX) PT Lowered to $0.20 at Jefferies

Pre-Open Stock Movers 01/03: (OHRP) (CELG) (DBVT) Higher; (AAPL) (LITE) (BMY) Lower (more...)

January 3, 2019 9:22 AM EST

Pre-Open Movers

Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) 73.6% HIGHER; announced today that it has entered into a definitive merger agreement with NeuBase Therapeutics, Inc., under which the stockholders of NeuBase would become the majority holders of the combined company. The proposed merger will create a public company focused on advancing NeuBases peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) 70.4% LOWER;... More

JMP Securities Downgrades Aevi (GNMX) to Market Perform

January 3, 2019 5:40 AM EST

JMP Securities analyst Jason Butler downgraded Aevi (NASDAQ: GNMX) from Market Outperform to Market Perform.

For an analyst ratings summary and ratings history on Aevi click here. For more ratings news on Aevi click here.

Shares of Aevi closed at $0.77 yesterday.

... More

After-Hours Movers 01/02: (GNMX) (LITE) (AAPL) Lower (more...)

January 2, 2019 6:04 PM EST

Today's After-Hours Movers

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) 70.4% LOWER; announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 400 mg BID) in children aged 6 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant... More

Aevi Genomic Medicine (GNMX) Reports ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD 'Did Not Achieve Statistical Significance on Primary Endpoint'

January 2, 2019 4:36 PM EST

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 400 mg BID) in children aged 6 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on... More

Aevi Genomic Medicine (GNMX) halted, news pending

January 2, 2019 4:27 PM EST

Aevi Genomic Medicine (NASDAQ: GNMX) halted, news pending

... More